SubsidieMeestersA breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.
Projectdetails
Introduction
Osteoarthritis is a debilitating disease affecting the joint and a leading cause of disability worldwide. It affects at least 250 million people and incurs healthcare costs of toward 0.5% of the GDP.
Project Overview
Peptinov is developing an active immunotherapy that can halt inflammation-driven destruction of the cartilage in the joints. We use a unique approach to neutralise a key pro-inflammatory protein (IL-6) driving chronic inflammation.
Mechanism of Action
Our vaccine-like approach stimulates the patient’s own immune system to produce antibodies against excess IL-6 and neutralise its biological function. By doing so, we will halt disease progression.
Cost Efficiency
Our treatment will cost 5-10% of conventional immunotherapies as we inject patients with inexpensive, immunogenic peptides to stimulate the production of endogenous antibodies.
Clinical Trials
Phase I clinical trial yielded very encouraging preliminary safety and tolerability data on 24 patients. This project will implement the Phase II clinical trial and make our therapy out-licensing ready.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.965.000 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 28-2-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- PEPTINOVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC COG | € 1.998.885 | 2023 | Details |
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
In Silico Trials for Cartilage Regenerative Medicine ApplicationsThe INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials. | ERC COG | € 2.212.385 | 2023 | Details |
NCM for osteoarthritisNC Biomatrix onderzoekt een innovatieve therapie voor artrose met notochordal cells, gericht op het herstellen van kraakbeenfunctie, met als doel een marktgereed product te ontwikkelen. | MIT Haalbaarheid | € 20.000 | 2021 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
In Silico Trials for Cartilage Regenerative Medicine Applications
The INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials.
NCM for osteoarthritis
NC Biomatrix onderzoekt een innovatieve therapie voor artrose met notochordal cells, gericht op het herstellen van kraakbeenfunctie, met als doel een marktgereed product te ontwikkelen.